Tags

Type your tag names separated by a space and hit enter

Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model.
Inflammopharmacology. 2018 Apr; 26(2):349-360.I

Abstract

Parkinson's disease (PD) pathology is characterized by the abnormal accumulation and aggregation of the pre-synaptic protein α-synuclein in the dopaminergic neurons as Lewy bodies (LBs). Curcumin, which plays a neuroprotective role in various animal models of PD, was found to directly modulate the aggregation of α-synuclein in in vitro as well as in in vivo studies. While curcumin has been shown to exhibit strong anti-oxidant and anti-inflammatory properties, there are a number of other possible mechanisms by which curcumin may alter α-synuclein aggregation which still remains obscure. Therefore, the present study was designed to understand such concealed mechanisms behind neuroprotective effects of curcumin. An animal model of PD was established by injecting lipopolysaccharide (LPS, 5 µg/5 µl PBS) into the substantia nigra (SN) of rats which was followed by curcumin administration (40 mg/kg b.wt (i.p.)) daily for a period of 21 days. Modulatory functions of curcumin were evident from the inhibition of astrocytic activation (GFAP) by immunofluorescence and NADPH oxidase complex activation by RT-PCR. Curcumin supplementation prevented the LPS-induced upregulation in the protein activity of transcription factor NFκB, proinflammatory cytokines (TNF-α, IL-1β, and IL-1α), inducible nitric oxide synthase (iNOS) as well as the regulating molecules of the intrinsic apoptotic pathway (Bax, Bcl-2, Caspase 3 and Caspase 9) by ELISA. Curcumin also resulted in significant improvement in the glutathione system (GSH, GSSG and redox ratio) and prevented iron deposition in the dopaminergic neurons as depicted from atomic absorption spectroscopy (AAS) and Prussian blue staining, respectively. Curcumin also prevented α-synuclein aggregates in the dopaminergic neurons as observed from gene as well as protein activity of α-synuclein using RT-PCR and IHC. Collectively, our results suggest that curcumin can be further pursued as a candidate drug in the molecules targeted therapy for PD and other related synucleopathies.

Authors+Show Affiliations

Department of Biophysics, Panjab University, Chandigarh, 160014, India.Department of Biophysics, Panjab University, Chandigarh, 160014, India. bnehru@pu.ac.in.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29027056

Citation

Sharma, Neha, and Bimla Nehru. "Curcumin Affords Neuroprotection and Inhibits Α-synuclein Aggregation in Lipopolysaccharide-induced Parkinson's Disease Model." Inflammopharmacology, vol. 26, no. 2, 2018, pp. 349-360.
Sharma N, Nehru B. Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model. Inflammopharmacology. 2018;26(2):349-360.
Sharma, N., & Nehru, B. (2018). Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model. Inflammopharmacology, 26(2), 349-360. https://doi.org/10.1007/s10787-017-0402-8
Sharma N, Nehru B. Curcumin Affords Neuroprotection and Inhibits Α-synuclein Aggregation in Lipopolysaccharide-induced Parkinson's Disease Model. Inflammopharmacology. 2018;26(2):349-360. PubMed PMID: 29027056.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model. AU - Sharma,Neha, AU - Nehru,Bimla, Y1 - 2017/10/12/ PY - 2017/09/09/received PY - 2017/09/24/accepted PY - 2017/10/14/pubmed PY - 2018/9/6/medline PY - 2017/10/14/entrez KW - Astrocyte activation KW - Glutathione homeostasis KW - NADPH oxidase complex KW - Neuroinflammation KW - α-Synuclein SP - 349 EP - 360 JF - Inflammopharmacology JO - Inflammopharmacology VL - 26 IS - 2 N2 - Parkinson's disease (PD) pathology is characterized by the abnormal accumulation and aggregation of the pre-synaptic protein α-synuclein in the dopaminergic neurons as Lewy bodies (LBs). Curcumin, which plays a neuroprotective role in various animal models of PD, was found to directly modulate the aggregation of α-synuclein in in vitro as well as in in vivo studies. While curcumin has been shown to exhibit strong anti-oxidant and anti-inflammatory properties, there are a number of other possible mechanisms by which curcumin may alter α-synuclein aggregation which still remains obscure. Therefore, the present study was designed to understand such concealed mechanisms behind neuroprotective effects of curcumin. An animal model of PD was established by injecting lipopolysaccharide (LPS, 5 µg/5 µl PBS) into the substantia nigra (SN) of rats which was followed by curcumin administration (40 mg/kg b.wt (i.p.)) daily for a period of 21 days. Modulatory functions of curcumin were evident from the inhibition of astrocytic activation (GFAP) by immunofluorescence and NADPH oxidase complex activation by RT-PCR. Curcumin supplementation prevented the LPS-induced upregulation in the protein activity of transcription factor NFκB, proinflammatory cytokines (TNF-α, IL-1β, and IL-1α), inducible nitric oxide synthase (iNOS) as well as the regulating molecules of the intrinsic apoptotic pathway (Bax, Bcl-2, Caspase 3 and Caspase 9) by ELISA. Curcumin also resulted in significant improvement in the glutathione system (GSH, GSSG and redox ratio) and prevented iron deposition in the dopaminergic neurons as depicted from atomic absorption spectroscopy (AAS) and Prussian blue staining, respectively. Curcumin also prevented α-synuclein aggregates in the dopaminergic neurons as observed from gene as well as protein activity of α-synuclein using RT-PCR and IHC. Collectively, our results suggest that curcumin can be further pursued as a candidate drug in the molecules targeted therapy for PD and other related synucleopathies. SN - 1568-5608 UR - https://www.unboundmedicine.com/medline/citation/29027056/Curcumin_affords_neuroprotection_and_inhibits_α_synuclein_aggregation_in_lipopolysaccharide_induced_Parkinson's_disease_model_ DB - PRIME DP - Unbound Medicine ER -